Nuclear EGFR contributes to acquired resistance to cetuximab
Open Access
- 17 August 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 28 (43), 3801-3813
- https://doi.org/10.1038/onc.2009.234
Abstract
Epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase involved in the etiology of several human cancers. Cetuximab is an EGFR-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma and metastatic colorectal cancer. Previous reports have shown that EGFR translocation to the nucleus is associated with cell proliferation. Here we investigated mechanisms of acquired resistance to cetuximab using a model derived from the non-small cell lung cancer line H226. We demonstrated that cetuximab-resistant cells overexpress HER family ligands including epidermal growth factor (EGF), amphiregulin, heparin-binding EGF and β-cellulin. Overexpression of these ligands is associated with the nuclear translocation of the EGFR and this process was mediated by the Src family kinases (SFK). Treatment of cetuximab-resistant cells with the SFK inhibitor, dasatinib, resulted in loss of nuclear EGFR, increased membrane expression of the EGFR and resensitization to cetuximab. In addition, expression of a nuclear localization sequence-tagged EGFR in cetuximab-sensitive cells increased resistance to cetuximab both in vitro and in mouse xenografts. Collectively, these data suggest that nuclear expression of EGFR may be an important molecular determinant of resistance to cetuximab therapy and provides a rationale for investigating nuclear EGFR as a biomarker for cetuximab response. Further, these data suggest a rationale for the design of clinical trials that examine the value of treating patients with cetuximab-resistant tumors with inhibitors of SFKs in combination with cetuximab.This publication has 47 references indexed in Scilit:
- Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancerMolecular Carcinogenesis, 2008
- Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expressionNucleic Acids Research, 2008
- Correlates and Determinants of Nuclear Epidermal Growth Factor Receptor Content in an Oropharyngeal Cancer Tissue MicroarrayCancer Epidemiology, Biomarkers & Prevention, 2008
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family membersOncogene, 2008
- Role of the Sec61 Translocon in EGF Receptor Trafficking to the Nucleus and Gene ExpressionMolecular Biology of the Cell, 2007
- Tyrosine phosphorylation controls PCNA function through protein stabilityNature, 2006
- Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathwayCancer Cell, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005
- Nuclear Localization of P185neu Tyrosine Kinase and Its Association with Transcriptional TransactivationBiochemical and Biophysical Research Communications, 1994
- Localization of epidermal growth factor receptor in hepatocyte nucleiJournal of Hepatology, 1991